Evidence of Mpox Virus Infection Among Persons Without Characteristic Lesions or Rash Presenting for First Dose of JYNNEOS Vaccine-District of Columbia, August 2022
- PMID: 36916132
- DOI: 10.1093/cid/ciad145
Evidence of Mpox Virus Infection Among Persons Without Characteristic Lesions or Rash Presenting for First Dose of JYNNEOS Vaccine-District of Columbia, August 2022
Abstract
We assessed mpox virus prevalence in blood, pharyngeal, and rectal specimens among persons without characteristic rash presenting for JYNNEOS vaccine. Our data indicate that the utility of risk-based screening for mpox in persons without skin lesions or rash via pharyngeal swabs, rectal swabs, and/or blood is likely limited.
Keywords: asymptomatic; mpox; pharyngeal swab; rectal swab.
Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023.
Conflict of interest statement
Potential conflicts of interest . The authors received no specific funding for this work. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.
Comment in
-
Neutralizing Antibody Titers Induced by JYNNEOS Vaccine in Unrecognized Previous Mpox Virus-Exposed Individuals.Clin Infect Dis. 2023 Nov 17;77(10):1484-1485. doi: 10.1093/cid/ciad412. Clin Infect Dis. 2023. PMID: 37417271 No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical